Interviews

Keeping up with fast-paced clinical, regulatory, and policy innovation in healthcare is difficult. Our video interviews provide insight from key experts in the field of biosimilars, and help keep you informed.
Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, considers whether a recent law could help biosimilars. 
Imron Aly, JD, partner at Schiff Hardin LLP, discusses the impact of listing patents in the FDA's Purple Book.
Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses whether including drugs' list prices in consumer advertising will help drive down prices for patients.
Imron Aly, JD, partner at Schiff Hardin LLP, discusses the Biosimilar Action Plan's key features.
Ha Kung Wong, JD, partner at Venable LLP, discusses how upcoming changes to the regulation of biologics are generating industry uncertainty. 
Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses whether companies' promises to stop raising drug prices will benefit patients.
Imron Aly, JD, partner at Schiff Hardin LLP, explains how European cases influenced US patent litigation over Humira. 
Ha Kung Wong, JD, partner at Venable LLP, addresses ongoing biosimilar cases that stakeholders are watching closely.
Ha Kung Wong, JD, partner at Fitzpatrick, Cella, Harper and Scinto, addresses recent changes to inter partes review (IPR) and post-grant review (PGR) proceedings with respect to biologic drugs.
Ha Kung Wong, JD, partner at Fitzpatrick, Cella, Harper and Scinto, discusses how manufacturers now approach the "patent dance" in light of Sandoz v Amgen.

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities


Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2018 Intellisphere, LLC. All Rights Reserved.